The final, formatted version of the article will be published soon.
BRIEF RESEARCH REPORT article
Front. Psychiatry
Sec. Behavioral and Psychiatric Genetics
Volume 15 - 2024 |
doi: 10.3389/fpsyt.2024.1416009
This article is part of the Research Topic Systems Biology Approaches to Psychiatric and Psychological Disorders: Unraveling the Complexities View all 5 articles
The effect size of rs521851 in the intron of MAGI2/S-SCAM on HADS-D scores correlates with EAT-26 scores for eating disorders risk.
Provisionally accepted- 1 St.Petersburg V.M.Bekhterev Psychoneurological Research Institute, Saint Petersburg, Russia
- 2 Federal Scientific Clinical Center of Physical and Chemical Medicine, Federal Medical & Biological Agency of Russia, Moscow, Moscow Oblast, Russia
- 3 Genotek LTD, Moscow, Moscow Oblast, Russia
- 4 Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, United States
An association between the MAGI2 (S-SCAM) intron variant rs521851 and depression symptoms, as measured by the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D), has been recently reported. The role of MAGI2 in depression has been linked to disruptions in the gut-brain axis. In this study, we investigated the association between rs521851 and HADS-D scores in an independent cohort of 380 individuals, consisting of 238 patients with an ICD-10 diagnosis of depression and 142 healthy controls. The original association was replicated in the patient cohort but not in the control group. Further analysis revealed that the effect size of rs521851 on HADS-D scores was moderated by Eating Attitudes Test 26 (EAT-26) scores. In participants with an EAT-26 score of ≥20, the effect size of rs521851 on HADS-D was more than 20 times greater compared to those with an EAT-26 score of <20. These findings successfully replicate the original association signal for MAGI2 and HADS-D, and highlight the role of MAGI2 in gut-brain interactions.
Keywords: GWAS, MAGI2, Depression, HADS-D, EAT 26
Received: 11 Apr 2024; Accepted: 30 Oct 2024.
Copyright: © 2024 Pinakhina, Kasyanov, Rukavishnikov, Larin, Veselovsky, Rakitko, Neznanov, Kibitov, Mazo and Artomov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Galina Mazo, St.Petersburg V.M.Bekhterev Psychoneurological Research Institute, Saint Petersburg, Russia
Mykyta Artomov, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.